NRX Pharmaceuticals, Inc. (NRXP) has 18 open-market insider trades by 9 insiders since 2021. The most active filer is Jonathan C. Javitt.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Jonathan C. Javitt | — | — | 6 | $6.5M | 2024-12-17 |
| Daniel C. Javitt | 10% Owner | — | 3 | $2.3M | 2022-11-30 |
| Chaim Hurvitz | Dir | — | 2 | $1.0M | 2023-08-30 |
| Alessandra Daigneault | CLOSecretary | — | 1 | $884K | 2021-09-02 |
| Robert Besthof | — | — | 1 | $470K | 2021-09-15 |
| Stephen H. Willard | CEO | — | 1 | $59K | 2022-12-16 |
| Seth van Voorhees | CFO | — | 2 | $51K | 2022-12-16 |
| Aaron Gorovitz | Dir | — | 1 | $11K | 2023-08-30 |
| Patrick John Flynn | Dir | — | 1 | $8K | 2022-11-28 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Jonathan C. Javitt | Chairman & 10% | Buy | $47K | 2024-12-17 |
| Aaron Gorovitz | Director | Buy | $11K | 2023-08-30 |
| Chaim Hurvitz | Director | Buy | $20K | 2023-08-30 |
| Jonathan C. Javitt | Chief Scientist & 10% | Buy | $33K | 2023-08-23 |
| Jonathan C. Javitt | — | Buy | $64K | 2023-08-22 |
| Seth van Voorhees | CFO | Buy | $33K | 2022-12-16 |
Companies that share insiders with NRXP, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Stephen H. Willard | CEO | Buy | $59K | 2022-12-16 |
| Jonathan C. Javitt | Director & 10% Owner | Sell | $400K | 2022-12-07 |
| Daniel C. Javitt | 10% | Sell | $33K | 2022-11-29 |
| Patrick John Flynn | Director | Buy | $8K | 2022-11-28 |
| Seth van Voorhees | CFO | Buy | $18K | 2022-11-25 |
| Daniel C. Javitt | 10% Owner | Sell | $307K | 2022-11-16 |
| Chaim Hurvitz | Director | Buy | $985K | 2022-11-16 |
| Daniel C. Javitt | 10% | Sell | $50K | 2022-11-11 |
| Daniel C. Javitt | 10% Owner | Sell | $1.6M | 2022-07-29 |